SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
HGSI Analysis & Videos »
HGSI: Bull or Bear?
BioMed News Bytes: Aldagen, Dyax, HGSI
HGSI
|
|
|
+52.64%
in
38 days
The <font> BioMedReports.com FDA Calendar service </font> includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results. <> On 6/8/09, Dyax Corp. (NASDAQ: DYAX) announced today that the FDA accepted the Co...
|
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
HGSI
|
|
|
-6.52%
in
3 days
(closed on 10/28/09)
<> <> On 7/15/09, Cadence Pharma (NASDAQ: CADX) announced that its New Drug Application (NDA) for Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the FDA and designated for a priority (six-month) review. The FDA has issued a PDUFA action date for the NDA of 11/13/09 for a possible decision by the Agency. The Company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and ...
|
New Indexes to Track Healthcare Trends and More
HGSI
|
|
|
+31.04%
in
82 days
(closed on 10/25/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP
HGSI
|
|
|
+6.62%
in
13 days
(closed on 08/04/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
FDA Calendar Updates: DDSS, HGSI, OREX, SPPI, TRIB
HGSI
|
|
|
-11.88%
in
3 hours
(closed on 07/20/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 263 entries as of 7/20/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
Bullish on HGSI ...
HGSI
|
|
|
+0.00%
in
4 minutes
(closed on 07/18/09)
Bio Pharm awaiting phase III fro the FDA. Approval will move this stock up big time. Denial will tank it. Many in PIII are approved but this specific approval is for a condition no other drug has been aprroved. It's risky but it looks good right now. Expect it swing until aporval as DT work the peaks and valleys. This stock can be worked that way, been getting an average of 8% the last three days.
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
HGSI
|
|
|
+240.97%
in
17 days
(closed on 07/20/09)
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
FDA Calendar Updates: BDSI, SVNT Deadlines Approach
HGSI
|
|
|
+0.00%
in
12 hours
(closed on 06/12/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Bullish on HGSI ...
HGSI
|
|
|
+2123.02%
in
232 days
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The companyÂ’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an e...
|
Emerging Biotech & Pharma Index: 36 More Companies
HGSI
|
|
|
+50.00%
in
111 days
(closed on 03/15/09)
<> 
The accompanying table [click to enlarge or download] includes the 36 remaining companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff.
However, several of the companies included in the remaining group of 36 have been in the news recently due to FDA related news . Late last week, Ligand Phar...
|
People Bullish on HGSI
People Bearish on HGSI
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on HGSI |
More Resources
|
About Human Genome Sciences Inc
- Answers.com
